{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:49:59Z","timestamp":1791614999629,"version":"4.3.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Early-stage accurate diagnosis of malignant pleural mesothelioma (MPM) has always been a formidable challenge. DNA and protein as biomarkers for the diagnosis of MPM have received considerable attention, and yet the outcomes are inconsistent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, a systematic search employing PubMed, EMBASE, and Cochrane Library to identify relevant studies from the first day of databases to October 2021. Moreover, we adopt the QUADAS-2 to evaluate the quality of eligible studies and Stata 15.0 and Review Manager 5.4 software programs to perform the meta-analysis. Additionally, bioinformatics analysis was performed at GEPIA for the purpose of exploring relationship between related genes and the survival time of MPM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 15 studies at the DNA level and 31studies at the protein level in this meta-analysis. All results demonstrated that the diagnostic accuracy of the combination of MTAP + Fibulin-3 was the highest with the SEN 0.81 (95% CI: 0.67, 0.89) and the SPE 0.95 (95% CI: 0.90, 0.97). And the bioinformatics analysis indicated that the higher MTAP gene expression level was beneficial to enhance the survival time of MPM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Nonetheless, as a result of the limitations of the included samples, it may be necessary to conduct additional research before drawing conclusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/inplasy.com\/inplasy-2022-10-0043\/<\/jats:ext-link>, identifier INPLASY2022100043.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1136049","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T05:21:50Z","timestamp":1681190510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic value of combination of biomarkers for malignant pleural mesothelioma: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Mucheng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: A surveillance, epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/his.13468","article-title":"Malignant mesothelioma in situ","volume":"72","author":"Churg","year":"2018","journal-title":"Histopathology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00408-013-9526-9","article-title":"Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos","volume":"192","author":"Bayram","year":"2014","journal-title":"Lung"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3510984","DOI":"10.1155\/2017\/3510984","article-title":"A novel panel of serum biomarkers for MPM diagnosis","volume":"2017","author":"Bonotti","year":"2017","journal-title":"Dis Markers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Trans Lung Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure","volume":"194","author":"Demir","year":"2016","journal-title":"Lung"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14712","article-title":"Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis","volume":"8","author":"Pei","year":"2017","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092210","article-title":"Systematic review, meta-analysis and bioinformatic analysis of biomarkers for prognosis of malignant pleural mesothelioma","volume":"12","author":"Lu","year":"2022","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/cncy.22509","article-title":"Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology","volume":"130","author":"Girolami","year":"2022","journal-title":"Cancer cytopathology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E96","DOI":"10.1111\/j.1365-2559.2012.04196.x","article-title":"The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas","volume":"60","author":"Zimling","year":"2012","journal-title":"Histopathology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Modern Pathol an Off J United States Can Acad Pathol Inc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12453","article-title":"BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests","volume":"66","author":"Hida","year":"2016","journal-title":"Pathol Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10653","article-title":"Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma","volume":"7","author":"Carbone","year":"2016","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000976","article-title":"Loss of BAP1 expression in atypical mesothelial proliferations helps to predict malignant mesothelioma","volume":"42","author":"Pillappa","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/his.13321","article-title":"Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours","volume":"71","author":"Yoshimura","year":"2017","journal-title":"Histopathology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer cytopathology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.02.004","article-title":"Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia","volume":"130","author":"Yoshimura","year":"2019","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Modern Pathol an Off J United States Can Acad Pathology Inc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0309-6","article-title":"Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma","volume":"33","author":"Kinoshita","year":"2020","journal-title":"Modern Pathol an Off J United States Can Acad Pathology Inc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22221","article-title":"Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"128","author":"Berg","year":"2020","journal-title":"Cancer cytopathology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/dc.24475","article-title":"HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion","volume":"49","author":"Hiroshima","year":"2021","journal-title":"Diagn cytopathology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12990","article-title":"Utility of highly expressed EZH2 in pleural effusion cytology for the diagnosis of mesothelioma","volume":"70","author":"Yoshimura","year":"2020","journal-title":"Pathol Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Internal Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2014.10.001","article-title":"Liquid biopsies in lung cancer: the new ambrosia of researchers","volume":"1846","author":"Rolfo","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12589","article-title":"Tumour biomarkers-tracing the molecular function and clinical implication","volume":"52","author":"Lin","year":"2019","journal-title":"Cell Proliferation"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22517","article-title":"A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications","volume":"57","author":"Volckmar","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040101","article-title":"Epigenetic modifications as biomarkers of tumor development, therapy response, and recurrence across the cancer care continuum","volume":"10","author":"Thomas","year":"2018","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1136049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T05:21:52Z","timestamp":1681190512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1136049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":30,"alternative-id":["10.3389\/fonc.2023.1136049"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1136049","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"article-number":"1136049"}}